

WHAT IS CLAIMED IS:

1. A method of modulating inflammation in a subject comprising:
administering a peptide agent comprising a sequence
5 corresponding to a partial-length T20/DP178 or T21/DP107FPR
antagonist.
2. An isolated complex comprising: a peptide agent having a
sequence that corresponds to T20/DP178, T21/DP107, or a
10 conservative variant or functional fragment thereof bound to an
FPR member.
3. A method of modulating an inflammatory response in a subject
comprising:
identifying a subject in need of a peptide agent that
15 interacts with an FPR member; and
administering to said subject an inflammatory response
modulating-amount of said peptide agent, wherein said peptide
agent comprises a sequence that corresponds to T20/DP178,
T21/DP107, or a conservative variant or functional fragment
20 thereof.
4. A method of modulating an inflammatory response in a subject
comprising:
administering to said subject an inflammatory response
modulating-amount of a peptide agent having a sequence that
corresponds to T20/DP178, T21/DP107, or a conservative variant
25 or functional fragment thereof; and
measuring the effect of said peptide agent as a ligand that
interacts with an FPR member.
5. A method of making a pharmaceutical product comprising:
providing a peptide agent having a sequence
30 corresponding to T20/DP178, T21/DP107, or a
conservative variant or functional fragment thereof;

providing a cell having thereon an FPR member that
interacts with said peptide agent;
contacting said peptide agent with said cell under
conditions that allow said peptide agent to interact with
said FPR member on said cell;
identifying the presence or absence of signal transduction
generated in response to the interaction of said peptide
agent with said FPR member; and
incorporating said peptide agent into said pharmaceutical
product, wherein said pharmaceutical product is an FPR
member antagonist if said signal transduction is identified
as being absent, and wherein said pharmaceutical product
is an FPR member agonist if said signal transduction is
identified as being present.

5

10

15

4005396-1004